Abstract: Described are transdermal drug delivery compositions comprising amphetamine, methods of making transdermal drug delivery compositions comprising amphetamine, and therapeutic methods of using them. In specific embodiments, the compositions are free of components with moieties that are reactive with amphetamine. In specific embodiments, the compositions are manufactured using solvents free of components with moieties that are reactive with amphetamine. Therapeutic methods using the compositions also are described.

Abstract: Hydrogels and hybrid hydrogels, methods of making the hydrogels/hybrid hydrogels, and methods of using the hydrogels/hybrid hydrogels. The hydrogels have polysaccharide moieties (e.g., chitosan or hyaluronic acid moieties). The hybrid hydrogels have polysaccharide moieties (e.g., chitosan or hyaluronic acid moieties) and poly(ester amide) moieties. The poly(ester amide) moieties can have one or more arginine moieties. The hydrogels/hybrid hydrogels can be used, for example, in consumer products and as cargo carrier materials (e.g., as therapeutic agent carriers).

Abstract: The present disclosure describes a gummy dosage form including: an amino acid in an amount of about 20% by weight or greater; a hydrophilic bulking agent; and a hydrophilic long-chain polymer, wherein at least a portion of the hydrophilic long-chain polymer comprises low methoxyl pectin. The gummy dosage forms can further include additives such as flavorants, fiber, and pH-adjusters. The disclosure further comprises methods for preparing such gummy dosage forms, wherein a hydrophilic bulking agent, a hydrophilic long-chain polymer, and water are combined to give a mixture and heated to give a hydrocolloid system in the form of a slurry; mixing an amino acid with the slurry; and setting the resulting mixture to give the gummy dosage form.

Abstract: Capsule shells and coatings can be prepared from an aqueous composition comprising a) at least 20 percent, based on the total weight of the aqueous composition, of a dispersed esterified cellulose ether comprising (i) groups of the formula —C(O)—R—COOA or (ii) a combination of aliphatic monovalent acyl groups and groups of the formula —C(O)—R—COOA, wherein R is a divalent aliphatic or aromatic hydrocarbon group and A is hydrogen or a cation, b) from 0.05 to 20 percent of a salt of a fatty acid, based on the weight of the dispersed esterified cellulose ether, and c) from 0.01 to 10 percent of an anionic surfactant comprising a sulfate or sulfonate group, based on the weight of the dispersed esterified cellulose ether.

Abstract: The invention provides a drug conjugate comprising: 1) a therapeutic agent that comprises a phosphate, phosphonate, carboxy, or phosphoramidate group, and 2) a fluorescent group linked to the phosphate, phosphonate, carboxy, or phosphoramidate group to form the corresponding ester and salts thereof. The conjugates are useful for therapy and as probes.

Abstract: Provided are compounds having the Formula I or II: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the treatment of cancers.

Abstract: Conjugates of a cholinesterase moiety and one or more nonpeptidic, water-soluble polymers are provided. Typically, the nonpeptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions to a patient.

Abstract: The present invention relates to the preparation and use of therapeutic compounds for the treatment of diseases at specific subcellular target areas such as specific cellular organelles. In particular, the therapeutic compounds of the invention are specific for modifying enzyme activity within targeted organelles or structures of cells and tissues. Subcellular organelles and structures that may be specifically targeted by compounds of the present invention include lysosomes, autophagasomes, the endoplasmic reticulum, the Golgi complex, peroxisomes, the nucleus, membranes and the mitochondria.

Abstract: An immunogenic product including IFN? coupled to a carrier protein molecule is capable to induce in vivo anti-IFN? antibodies and is useful in treating IFN? related conditions.

Abstract: A therapeutic method for mitigating bone loss. This method includes preparing and administering to animals intraperitoneally or orally a therapeutic agent containing metallic gold cluster molecules as an active ingredient.

Abstract: An affinity binding moiety comprising an antigen recognition region which comprises complementarity determining region (CDR) amino acid sequences as set forth in heavy chain ordered N to C terminus: SEQ ID NOs: 4, 6 and 8, and light chain ordered N to C terminus: SEQ ID NOs: 12, 14 and 16 is disclosed. A pharmaceutical compositions comprising as an active ingredient the affinity binding moiety is also disclosed. Methods of diagnosing, preventing or treating an autoimmune disease or a cancer associated with an expression of NKp46 are also disclosed.

Abstract: The present invention relates to modified citrullinated enolase peptides that can be used as targets for cancer immunotherapy. These peptides can be used as vaccines or as targets for monoclonal antibody (mAb) therapy. Such vaccines or mAbs may be used in the treatment of cancer.

Abstract: Provided herein are methods and immunoconjugate dimer compositions for the treatment of diseases associated with angiogenesis and neovascularization. In one aspect, the invention relates to a method for treating wet age-related macular degeneration (AMD) in an eye of a patient in need thereof. The method comprises administering to the patient in multiple dosing sessions, a composition comprising an effective amount of an immunoconjugate dimer, wherein the monomer subunits of the dimer each comprises a mutated human factor VIIa (fVIIa) protein conjugated to the human immunoglobulin G1 (IgG1) Fc domain.

Abstract: Disclosed is a method of treating an ocular disorder, comprising contacting the eye of a subject in need thereof with an effective amount of a therapeutic nanoparticle composition, the therapeutic nanoparticle composition comprising (i) at least one population of nanostructures, (ii) a peptide attached to the at least at least one population of nanostructures, (iii) a therapeutic agent useful for the treatment of the ocular disorder attached to the at least one population of nanostructures or to the peptide; and (iv) optionally, a linkage between the at least one population of nanostructures or the peptide and the therapeutic agent.

Abstract: The present invention relates to the 14-3-3 protein which is a non-alcoholic fatty liver regulating factor. According to the present invention, two isoform proteins of 14-3-3, i.e., 14-3-3? and 14-3-3?, are different regulating factors for regulating the transcriptional activity of PPAR?2. 14-3-3? increases the transcriptional activity of PPAR?2 by binding to PPAR?2, on the other hand, 14-3-3? plays a role in decreasing the transcriptional activity of PPAR?2. Thus, 14-3-3? and 14-3-3?, which are PPAR?2 regulating factors, are proteins that play a vital role in lipid metabolism, and may be used as a target for the prevention or treatment of fatty liver.

Abstract: The present invention relates to RNA containing compositions for use in the treatment or prophylaxis of tumor and/or cancer diseases, to a pharmaceutical composition, to a kit and to uses of the RNA containing compositions for the treatment or prophylaxis of tumor and/or cancer diseases.

Abstract: This invention relates to biotechnology, more particularly, to water-soluble polymeric delivery systems for the imaging, evaluation and/or treatment of rheumatoid arthritis and other inflammatory diseases. Using modern MR imaging techniques, the specific accumulation of macromolecules in arthritic joints in adjuvant-induced arthritis in rats is demonstrated. The strong correlation between the uptake and retention of the MR contrast agent labeled polymer with histopathological features of inflammation and local tissue damage demonstrates the practical applications of the macromolecular delivery system of the invention.

Abstract: The present invention provides a method for the commercial presentation of a solution of gadolinium-DOTA that provides certain advantages over the known methods.

Abstract: Compounds as defined herein are provided which are useful in (1) diagnostic methods for detecting and/or identifying cells presenting PSMA; (2) compositions comprising a compound of the invention together with a pharmaceutically acceptable diluent; and (3) methods for imaging prostate cancer cells.

Abstract: A method of reducing radiation exposure of a non-cancerous tissue of a patient diagnosed with a cancer includes administering to the patient an agent capable of competing for binding sites on a surface of the non-cancerous tissue, provided that the administration is carried out after a waiting period that follows administration of a compound including a radionuclide to the patient, the compound having affinity for both a cancerous tissue and the non-cancerous tissue, and, further provided that the binding sites have an affinity for both the agent and the compound.

Abstract: An apparatus includes a fluid reservoir, a sterilization member, and a transfer adapter. The sterilization member operably couples to the fluid reservoir. The sterilization member is configured to be transitioned between a first configuration, in which the sterilization member obstructs an inlet surface of the fluid reservoir and maintains the inlet surface in a substantially sterile environment, and a second configuration, in which the inlet surface is unobstructed. The transfer adapter is configured to be placed in fluid communication with a portion of a patient. The transfer adapter is configured to move relative to the sterilization member from a first position to a second position such that a surface of the transfer adapter contacts the sterilization member to transition the sterilization member to the second configuration. The fluid reservoir is placed in fluid communication with the transfer adapter when the transfer adapter is in the second position.

Abstract: Treatment systems, devices, articles, and associated methods of operation for treating open wounds are disclosed herein. In one embodiment, a method includes applying a first material and a second material to be in contact with a surface of the open wound having a water content at the surface and applying a voltage differential to the first and second materials, thereby producing hydrogen peroxide (H2O2) at the surface via an electrochemical reaction between oxygen (O2) in air and water (H2O) in the water content at the surface. The voltage differential is calibrated to correspond to a concentration of the produced hydrogen peroxide in the water content effective in reducing or preventing a bacterial infection at the surface of the open wound.

Abstract: The present invention relates to methods and devices for diminishing microbes. The invention provides methods and devices to sanitize, disinfect and sterilize areas, spaces, surfaces and items as well as to sanitize human skin. The methods and devices will be of major importance to the healthcare industry and to other industries or physical environments that require sanitizing, disinfecting or sterilizing. The methods comprise the use of near infrared light (NIR), UV, violet and blue emitting LED elements as well as OLED (Organic Light-Emitting Diodes) as a stand-alone technology. Optionally the system may be used in combination with ozone and ionized silver.

Abstract: Provided herein are portable ultraviolet (UV) devices, systems, and methods of use and manufacturing same. Methods of use include methods for UV disinfection and sterilization, more specifically, methods for UV disinfection and sterilization of a container, a room, a space or a defined environment. The portable UV devices, systems and methods are particularly useful for the UV disinfection and sterilization of a container, a room, a space or defined environment used in the food, beverage and dairy industry and in the process of fermentation for an alcoholic beverage. Provided are also portable UV devices, systems, and methods for inhibiting the growth of one or more species of microorganisms present in a container, a room, a space or a defined environment, preferably for inhibiting the growth of one or more species of microorganisms present on an interior surface of a container, a room, a space or a defined environment.

Abstract: A catheter which is one mode of a medical conduit of the present invention is placed inside a human body from the outside of the human body through human tissue. The catheter has a light introducing portion. The light introducing portion is provided on an outer wall surface of the catheter located on the outside-of-human-body side, and allows at least a part of ultraviolet light irradiated from the outside of the catheter to be totally reflected at an inner wall surface of the catheter toward the inside-of-human-body side.

Abstract: An ice machine prevents micro-organism growth by utilizing a clean-in-place process. The ice making process of the ice making machine is turned OFF, and then ozonated water, from an ozonated water generation system, is pumped into a distribution system, within the ice making machine so that the ozonated water is sprayed onto surfaces of the ice making machine which are susceptible to micro-organism growth and/or scale. Exposing the surfaces to ozonated water kills the micro-organisms and rinses the dead micro-organisms out of the ice making machine.

Abstract: Liquid water detection in a sterilization chamber that can distinguish liquid water from material in the load that is outgassing and can dry the liquid, is independent of the vacuum pump and chamber leak rate, and that is capable of detecting small amounts of liquid and drying the liquid without freezing the liquid in the process is achieved by monitoring conditions in the chamber at two different pressures, one above the boiling point of water and another below the boiling point of water at a given load temperature.

Abstract: The present invention extends to methods, apparatus, and systems for disinfecting articles with ozone. Aspects of the invention use increased concentrations ozone in sealed, confined volumes, such as, for example, carts, lockers, cabinets, etc. to disinfect or sterilize medical articles. A medical article is placed in a confined volume. The confined volume is sealed so that the atmosphere inside the sealed, confined volume is isolated from the external atmosphere. The concentration of ozone in the sealed, confined volume is rapidly increased to a threshold concentration. At the threshold ozone concentration, the medical article can be disinfection or sterilized in a reduce amount of time. When disinfection or sterilization is complete, the concentration of ozone in the sealed, confined volume is rapidly reduced to a safe level. The sealed, confined volume is unsealed. The disinfected or sterilized medical article can be removed from the confined volume.

Abstract: A medical device packaging container housing a medical device and being configured for high pressure steam sterilization includes: a main body part that includes an open upper face part and a bottom part, wherein the upper face part includes a lid member fixing part for attachment of a peelable sheet-shaped lid member; and a water dispersion part disposed in a peripheral part of the bottom part along a side wall of the main body part, and being configured to disperse water stored in the peripheral part.

Abstract: A water-based fragrance composition comprises at least about 67 wt % water and between about 5 and about 17 wt % of a first organic solvent, wherein the first organic solvent comprises one or more relatively volatile, water soluble, low molecular weight organic compound(s) having a boiling point less than about 100° C. The water-based fragrance composition further comprises about 5 wt % or less of at least one fragrance formulation and between about 0 and about 22 wt % of a second organic solvent, wherein the second organic solvent comprises one or more moderately volatile, water soluble organic compound(s) having a boiling point greater than or equal to about 100° C. and less than or equal to about 300° C.

Abstract: A pod for removing odor and moisture from a substantially confined area has deodorant and moisture adsorbing properties to counteract unpleasant odours, especially odours due to microbial growth. The pod is removably insertable into footwear, gloves, skates, lockers, sports gear, workout gear or any gear or enclosure. The pod has a fabric pouch with anti-microbial properties and contains fragrance-releasing particles and desiccant granules. The moisture adsorbing properties of the pod may be thermally rechargeable. The pods may be attached to other pods in use.

Abstract: An electronic apparatus capable of controlling the air purification performance of a photocatalytic filter according to an air volume of a blowing fan and a concentration of a specific gas. An electronic apparatus having a deodorizing performance recovery function of a photocatalytic filter. The electronic apparatus includes a blowing fan, a filter apparatus configured to purify air introduced by the blowing fan and a controller configured to adjust a current applied to the filter apparatus, wherein the filter apparatus comprises a light emitting module to which a plurality of light emitting portions configured to output ultraviolet light is mounted, a photocatalytic filter provided to face the light emitting portion and a support frame configured to support the light emitting module and the photocatalytic filter to be apart from each other by a predetermined distance.

Abstract: A filtering apparatus includes a filter with meshes having a periphery enclosed by a metal frame, an antibacterial material layer formed on the filter, a negative ions generator stretching into the filter for generating negative oxygen ions, and an electrode plate disposed on the metal frame. The metal frame is affected by the electrode plate to produce a high voltage electric field, thereby activating the antibacterial material layer under a piezoelectric effect to release more negative oxygen ions and silver ions. The negative oxygen ions and the silver ions collide together within the filter and become finer, thereby absorbing smelly odor passing through the filter to the maximum extent, purifying air, destroying germs, and promoting the air quality of the environment.

Abstract: An extruded water-soluble article is made from homogeneous material that includes a water-soluble polymer having an extrusion temperature of 50 to 150° C. This relatively low extrusion temperature is compatible with actives that would otherwise be destroyed in a high temperature extrusion process. The article further includes between 0.1% to 50% by weight of an active agent.

Abstract: Embodiments of the present technology may permit for native, intact, natural, human-derived, or allograft-derived fibers to be used as threads for suturing. Embodiments may include a thread for suturing. The thread may include a first portion, which includes a fascia fiber. The first portion may have a first end that includes the fascia fiber. The thread may also include a second portion including a non-human-derived fiber. The second portion may have a first end that includes the non-human-derived fiber. The first end of the second portion may be attached to the first end of the first portion. Embodiments may include a method of forming a thread. The method may include attaching a first end of a fascia fiber to a first end of a first non-human-derived fiber. The method may also include attaching a second end of the fascia fiber to a first end of a second non-human-derived fiber.

Abstract: Provided is a method of making a polymeric material with a spatially controlled distribution of one or more additives including the steps of blending the one or more additives with a polymeric material, consolidating the polymeric material, heating at least a portion of at least one surface of the consolidated additive-blended polymeric material, and cooling the heated consolidated additive-blended polymeric material, thereby forming a polymeric material with a spatially controlled distribution of additive.

Abstract: Methods and devices for the repair of articular tissue using collagen material are provided. Compositions of collagen material and related kits are also provided.

Abstract: Disclosed herein are improved surgical techniques for repairing bone defects in a sternum during a sternotomy procedure and implants adapted for such techniques. In an exemplary embodiment, provided is a fusion strip made of an osteoconductive material and of a dimension that is especially adapted for improved repair of sternal bone defects.

Abstract: Provided herein are methods of producing an acellular tissue product wherein the method can include the step of inducing apoptosis and washing the tissue after induction of apoptosis with a tonic solution. Also provided herein are acellular tissue products produced by the methods provided herein and methods of administering the acellular tissue products to a subject in need thereof.

Abstract: A method for cartilage tissue engineering including fabricating a nanocomposite, injecting the nanocomposite into a defect site of cartilage, and forming a hydrogel in the defect site of the cartilage using a sol-gel transition responsive to increasing temperature of the nanocomposite from room temperature to 37° C. Fabricating a nanocomposite includes forming an activated copolymer by functionalizing a copolymer, forming a conjugated copolymer by grafting the activated copolymer to a polysaccharide, forming a protein-conjugated copolymer by crosslinking a protein with the conjugated copolymer, forming the nanocomposite by adding a plurality of nanoparticles to the protein-conjugated copolymer.

Abstract: The present invention relates to an implant having a surface comprising a coating on at least a portion of the surface of the implant, wherein the coating comprises at least two coating layers of bioactive compounds adjacent to each other, obtainable in a process comprising the following steps: providing an implant with a surface, providing a first suspension comprising at least one first bioactive compound in a first solvent, wherein the first bioactive compound is non-soluble or partially soluble in the first solvent, applying said first suspension comprising the at least one first bioactive compound onto at least a part of the implant surface forming a first coating layer; drying the first coating layer, providing a second solution comprising at least one second bioactive compound in a second solvent, wherein the second bioactive compound is soluble or readily soluble in the second solvent; applying said second solution comprising the at least one second bioactive compound onto the first coating layer form

Abstract: The present disclosure relates to medical devices, and methods for producing and using the devices. In embodiments, the medical device may be a buttress including a porous substrate possessing a therapeutic layer of a chemotherapeutic agent and optional excipient(s) thereon. By varying the form of chemotherapeutic agents and excipients, the medical devices may be used to treat both the area to which the medical device is attached as well as tissue at a distance therefrom.

Abstract: The invention comprises self-lubricating polymer compositions that are especially useful in medical devices and valves and gaskets of medical devices. In a preferred embodiment, the polymer compositions comprise a thermosetting or thermoplastic silicone elastomer in combination with a lubricity enhancing polyfluoropolyether fluid or hydrocarbon-based synthetic oil. In other preferred embodiments, the polymer compositions contain only biocompatible components. The improved anti-friction properties of the self-lubricating polymers can be demonstrated over a course of insertion and withdrawal cycles, where conventional polymers have changing and mostly increasing force required for each insertion and withdrawal, while the polymer compositions of the invention remain stable.

Abstract: The disclosure concerns various medical devices implemented to provide a nitric oxide rich environment for anti-microbial or anti-thrombogenic benefits. The medical device generally includes a nitric oxide donor material that is contained within a sealed cavity, and a transport medium that defines and captivates the entirety of the cavity, wherein the transport medium is permeable to both water and nitric oxide. As the nitric oxide donor material becomes saturated with water from the surrounding tissue or fluids, nitric oxide is chemically released, and the resulting nitric oxide is communicated through the transport medium to a treatment site for anti-microbial and anti-thrombogenic benefits.

Abstract: A syringe includes a syringe body, a syringe cone having a distal opening, and a connection arranged in the region of the syringe cone, wherein the syringe body includes a first material and the connection includes a second material, and wherein the first material is different from the second material and the second material is a softer material than the first material.

Abstract: The present invention is directed to improved coatings and coating methods for medical devices.

Abstract: The present disclosure relates to the field of medical treatment. More particularly, the current invention delivers medication via a coating via a hydrogel infused with pharmaceutical compounds into the bloodstream to promote the supply to the distal vascular bed beyond the stent. The present invention uses in a preferred embodiment a stent with a thin coating of biodegradable or non-biodegradable hydrogel designed to ameliorate or eliminate vasospasms or thromboses, or to treat cancer, which hydrogel may optionally be impregnated with pharmaceutical compounds. The present invention also teaches the use of thin hydrogel coatings to ameliorate treatment related difficulties.

Abstract: The present disclosure discloses a hybrid implant system for fixing and repairing orthopedic fracture and a manufacturing method therefor. The hybrid implant system comprises an implant body having holes on both ends and a locking part configured for attaching the implant body to a broken bone through the holes. The hybrid implant system further comprises a healing assembly made from a material promoting healing of the bone. The implant body has at least one window on a side, the at least one window is aligned with a broken location of the bone, and the healing assembly is inserted into the window in a self-locking manner towards an interior of the implant body.

Abstract: The invention includes an implantable composition for management of pain in animals. The composition includes one or more active ingredients, a biocompatible polymer based drug delivery matrix, and other compounds to facilitate composition manufacture and durability. The composition disclosed herein is administered as a veterinary implant device. The implant is inserted subcutaneously into a patient and is designed to function in vivo for prolonged periods of time ranging from multiple weeks to months or even years. Accordingly, the composition must provide a constant release of one or more active ingredients over an extended period of time. To enable combination therapy for pain management, the composition may also include one or more layers of active ingredients seeded into one or more drug delivery systems. Multiple compositions having one or more layers loaded with different active ingredients may also be used in combination therapies.

Abstract: Illustrative embodiments of new and useful systems and methods for reduced-pressure therapy are described. One example embodiment is a manually-actuated pump for applying reduced-pressure therapy. The pump generally comprises a charging chamber, a regulated chamber, and a regulator passage between the charging chamber and the regulated chamber. A valve body controls fluid communication through the regulator passage, and a regulator spring may be engaged with the valve body to bias the valve body against a differential between a pressure in the regulated chamber and an ambient pressure. The regulator passage may have a bore size adapted deflect the valve body to cause an audible indication of a leak.